29.82
-0.52 (-1.71%)
| Previous Close | 30.34 |
| Open | 30.94 |
| Volume | 1,946,200 |
| Avg. Volume (3M) | 1,184,543 |
| Market Cap | 1,703,233,408 |
| Price / Earnings (TTM) | 43.85 |
| Price / Earnings (Forward) | 204.08 |
| Price / Sales | 8.63 |
| Price / Book | 5.53 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 26.33% |
| Operating Margin (TTM) | 70.15% |
| Diluted EPS (TTM) | 0.820 |
| Quarterly Revenue Growth (YOY) | 3,661.10% |
| Total Debt/Equity (MRQ) | 1.20% |
| Current Ratio (MRQ) | 8.41 |
| Operating Cash Flow (TTM) | 69.54 M |
| Levered Free Cash Flow (TTM) | 60.20 M |
| Return on Assets (TTM) | 7.81% |
| Return on Equity (TTM) | 20.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Stoke Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.57% |
| % Held by Institutions | 114.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Skorpios Trust | 30 Sep 2025 | 2,256,181 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 39.00 (BTIG, 30.79%) | Buy |
| Median | 32.00 (7.31%) | |
| Low | 25.00 (JP Morgan, -16.16%) | Hold |
| Average | 31.80 (6.64%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 24.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 05 Nov 2025 | 39.00 (30.78%) | Buy | 22.82 |
| 13 Oct 2025 | 39.00 (30.78%) | Buy | 30.34 | |
| Canaccord Genuity | 05 Nov 2025 | 28.00 (-6.10%) | Buy | 22.82 |
| Wedbush | 05 Nov 2025 | 32.00 (7.31%) | Buy | 22.82 |
| JP Morgan | 03 Nov 2025 | 25.00 (-16.16%) | Hold | 26.10 |
| Needham | 10 Oct 2025 | 35.00 (17.37%) | Buy | 30.19 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KRAINER ADRIAN R. | - | 30.34 | -40,472 | -1,227,920 |
| Aggregate Net Quantity | -40,472 | |||
| Aggregate Net Value ($) | -1,227,920 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 30.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KRAINER ADRIAN R. | Director | 24 Nov 2025 | Automatic sell (-) | 40,472 | 30.34 | 1,227,920 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |